Scientific Breakthrough: New Immunotherapy Reprograms Dormant Cells to Reverse Chronic Airway Inflammation in Allergic Asthma

Researchers discover a way to reawaken dormant immune cells using the Dectin-1 receptor, providing a new epigenetic treatment for chronic asthma inflammation.

By: AXL Media

Published: Apr 1, 2026, 9:06 AM EDT

Source: Information for this report was sourced from News Medical

The Molecular Basis of Respiratory Failure

Allergic asthma is defined by a chronic and often debilitating inflammatory response in the airway, resulting in mucus overproduction and structural remodeling of the bronchial tubes. For years, the scientific community has attributed this pathology to a fundamental imbalance between the cells that trigger inflammation and the regulatory T cells (Tregs) meant to suppress it. New research published in Life Science Alliance suggests that the root cause of this imbalance is not just a lack of these protective cells, but a state of "cellular senescence" where the cells become dormant. This dormant state prevents the immune system from self-regulating, allowing allergens to trigger runaway inflammation that standard treatments often fail to fully suppress.

Reawakening the Body’s Natural Defenses

The collaborative study, involving experts from Zhengzhou University and the Shenzhen University School of Medicine, focused on a specific surface protein called the Dectin-1 receptor. Researchers hypothesized that this receptor acts as a biological switch that can be used to "re-educate" compromised immune cells. By using a small peptide labeled KQS-1, the team was able to engage this receptor and trigger a series of metabolic and epigenetic changes. This process effectively "reawakened" the dormant cells, renewing their ability to function as the body's primary defense against allergic overreaction.

Restoring Essential Genetic Markers

A critical component of this therapy involves the restoration of two specific proteins: the transcription factor FOXP3 and the signaling molecule IL-10. In patients suffering from chronic asthma, these proteins are often absent or significantly reduced, leading to a profound failure of the immune system’s regulatory capacity. The new therapy works by reprogramming the epigenetic landscape of the cell, allowing the FOXP3 and IL-10 genes to be expressed once again. Co-senior author Liguo Li noted that this genetic restoration appears to be stable and long-lasting, providing a durable solution rather than a temporary suppression of symptoms.